Drugs / L608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05938946 | Aug 2023 → Sep 2024 | pulmonary arterial hypertension | Pharmosa Biopharm Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05938946 ↗ |
| Route | Inhaled | “L608 inhalation Solution (L608) is developed by Pharmosa Biopharm Inc. (PBI) as a new liposomal Iloprost formulation for inhalation use” NCT05938946 ↗ |